23andMe to Report Q2 FY2025 Financial Results
2024年11月7日 - 9:30PM
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human
genetics and biopharmaceutical company, announced today that it
will report financial results for the second quarter of fiscal year
2025 (FY2025) after the market closes on Tuesday, November 12,
2024. The Company will webcast a conference call at 4:30 p.m.
Eastern Time on that date to discuss the quarter’s results and
report on business progress.
The webcast can be accessed on the day of the event at this
link. A webcast replay will be available at the same address
following the event. In addition, 23andMe will use the Say
Technologies platform to allow retail and institutional
shareholders to submit and upvote questions to management in
advance of the earnings conference call. Shareholders can submit
questions by visiting this link. The Q&A platform will remain
open until 24 business hours before the earnings call.
About 23andMe23andMe is a genetics-led consumer
healthcare and therapeutics company empowering a healthier future.
For more information, please visit investors.23andme.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, including, without
limitation, statements regarding the future performance of
23andMe’s businesses in consumer genetics and therapeutics and the
growth and potential of its proprietary research platform. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding
23andMe’s strategy, financial position, financial projections,
funding for continued operations, cash reserves, projected costs,
database growth, plans, and objectives of management, are
forward-looking statements. The words "believes," "anticipates,"
"estimates," "plans," "expects," "intends," "may," "could,"
"should," "potential," "likely," "projects," “predicts,”
"continue," "will," “schedule,” and "would" or, in each case, their
negative or other variations or comparable terminology, are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. These
forward-looking statements are predictions based on 23andMe’s
current expectations and projections about future events and
various assumptions. 23andMe cannot guarantee that it will actually
achieve the plans, intentions, or expectations disclosed in its
forward-looking statements and you should not place undue reliance
on 23andMe’s forward-looking statements. These forward-looking
statements involve a number of risks, uncertainties (many of which
are beyond the control of 23andMe), or other assumptions that may
cause actual results or performance to differ materially from those
expressed or implied by these forward-looking statements. The
forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described from
time to time in the Company’s filings with the Securities and
Exchange Commission, including under Item 1A, “Risk Factors” in the
Company’s most recent Annual Report on Form 10-K, as filed with the
Securities and Exchange Commission, and as revised and updated by
our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
The statements made herein are made as of the date of this press
release and, except as may be required by law, 23andMe undertakes
no obligation to update them, whether as a result of new
information, developments, or otherwise.
ContactsInvestor Relations Contact:
investors@23andme.comMedia Contact:
press@23andMe.com
23andMe (NASDAQ:ME)
過去 株価チャート
から 11 2024 まで 12 2024
23andMe (NASDAQ:ME)
過去 株価チャート
から 12 2023 まで 12 2024